Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Status:
Withdrawn
Trial end date:
2020-03-24
Target enrollment:
Participant gender:
Summary
Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after
histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days
followed by a prostatectomy thereafter.
Tumor material and blood samples will be analysed before, during and after the treatment with
Ruxolitinib.